Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers
API SUPPLIERS
Curia - Accelerating therapies from discovery to commercialization with flexible, scalable CDMO solutions.
China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress
Maithri Drugs: Dedicated to your API needs.
ApiSyn: From early-phase research and process development to reliable cGMP manufacturing worldwide.
Saiming Pharmaceutical – Delivering innovative, sustainable chemical solutions with global reach and 12+ years of trusted excellence.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
17
PharmaCompass offers a list of Remibrutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Remibrutinib manufacturer or Remibrutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Remibrutinib manufacturer or Remibrutinib supplier.
A Remibrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Remibrutinib, including repackagers and relabelers. The FDA regulates Remibrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Remibrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Remibrutinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Remibrutinib supplier is an individual or a company that provides Remibrutinib active pharmaceutical ingredient (API) or Remibrutinib finished formulations upon request. The Remibrutinib suppliers may include Remibrutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Remibrutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Remibrutinib Drug Master File in Korea (Remibrutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Remibrutinib. The MFDS reviews the Remibrutinib KDMF as part of the drug registration process and uses the information provided in the Remibrutinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Remibrutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Remibrutinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Remibrutinib suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Remibrutinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Remibrutinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Remibrutinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Remibrutinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Remibrutinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Remibrutinib suppliers with NDC on PharmaCompass.
Remibrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Remibrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Remibrutinib GMP manufacturer or Remibrutinib GMP API supplier for your needs.
A Remibrutinib CoA (Certificate of Analysis) is a formal document that attests to Remibrutinib's compliance with Remibrutinib specifications and serves as a tool for batch-level quality control.
Remibrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Remibrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Remibrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Remibrutinib EP), Remibrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Remibrutinib USP).
